Endeavour creates new intermediates for prion drug developers
in-pharmatechnologist.com spoke with Jordi Robinson from Enveavour at CPhI in Frankfurt, Germany who explained that the firm developed the new intermediates after recognising their potential as the building blocks for aminothiazoles, many of which are being examined as potential prion disease treatments.
“Earlier this year there was an article in the Journal of Medicinal Chemistry which highlighted quite clearly to use that aminothiazoles are currently forming an important class of therapeutic class for treating prion diseases like Creutzfeldt-Jakob disease.
“We took a step back from that and took a look at these aminothiazoles to see what sort of building block we could make to aid research in this area… and we’ve designed a set of what are commercially novel thioureas basically to aid in the research and development of these new therapeutic leads.”
He added that the new pyridinyl thioureas will be distributed by Endeavours partner Alfa Aesar in an exclusive agreement.
Robinson also spoke about demand for the new intermediates, explaining that the firm is seeing strong interest from small molecule and biotechnology companies interested in develop therapeutic leads that can be outlicensed to Big Pharma pipelines.
